Impact of vancomycin or linezolid therapy on development of renal dysfunction and thrombocytopenia in Japanese patients

Chemotherapy

Volumn 59, Issue 5, 2014, Pages 319-324

  Fujii, Satoshi ^a,c   Takahashi, Satoshi ^b   Makino, Shinki ^a   Kunimoto, Yusuke ^a   Nakata, Hiromasa ^a   Noda, Norimasa ^a   Sakurai, Koichi ^c   Miyamoto, Atsushi ^a  

^a SAPPORO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Linezolid; Renal dysfunction; Thrombocytopenia; Vancomycin

Indexed keywords

LINEZOLID; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ADVERSE OUTCOME; ANTIBIOTIC THERAPY; ARTICLE; FEMALE; HUMAN; INFECTION; JAPANESE (PEOPLE); KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ADULT; CONFERENCE PAPER; GLOMERULUS FILTRATION RATE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT INDICATION; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG MONITORING; MIDDLE AGED; PROCEDURES; RENAL INSUFFICIENCY; TIME; VERY ELDERLY; YOUNG ADULT;

ACETAMIDES; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; PLATELET COUNT; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TIME FACTORS; VANCOMYCIN; YOUNG ADULT;

EID: 84893204588     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000356756     Document Type: Article

References (24)

1. Moellering RC Jr: Vancomycin: a 50-year reassessment. Clin Infect Dis 2006; 42(suppl 1): S3-S4.
2. Levine DP: Vancomycin: a history. Clin Infect Dis 2006; 42(suppl 1):S5-S12.
3. Attassi K, Hershberger E, Alam R, Zervos MJ: Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34: 695-698.
4. Lu PL, Wang JT, Chen CJ, Chen WC, Chen TC, Hwang YC, Chang SC: Compassionate use of linezolid for adult Taiwanese patients with bone and joint infections. Chemotherapy 2010; 56: 429-435.
5. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP: Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
6. Begg EJ, Barclay ML, Kirkpatrick CMJ: The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 2001; 52(suppl 1): 35S-43S.
7. Suzuki Y, Kawasaki K, Sato Y, Tokimatsu I, Itoh H, Hiramatsu K, Takeyama M, Kadota J: Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chemotherapy 2012; 58: 308-312.
8. Brier ME, Stalker DJ, Aronoff GR, Batts DH, Ryan KK, O'Grady M, Hopkins NK, Jungbluth GL: Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47: 2775-2780.
9. Lin YH, Wu VC, Tsai IJ, Ho YL, Hwang JJ, Tsau YK, Wu CY, Wu KD, Hsueh PR: High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents 2006; 28: 345-351.
10. Wu VC, Wang YT, Wang CY, Tsai IJ, Wu KD, Hwang JJ, Hsueh PR: High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42: 66-72.
11. Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Tsuchida T, Tatsumi S, Ishihara M, Ikeuchi H, Uchino M: Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother 2011; 17: 382-387.
12. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B: Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2002; 34: 1481-1490.
13. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH: Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-1797.
14. Walkey AJ, O'Donnell MR, Wiener RS: Linezolid vs. glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2011; 139: 1148-1155.
15. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J: Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54: 621-629.
16. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
17. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 suppl 1):S1-S266.
18. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
19. Kullar R, Davis SL, Levine DP, Rybak MJ: Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52: 975-981.
20. Rodriguez Colomo O, Álvarez Lerma F, González Pérez MI, Sirvent JM, García Simón M: Impact of administration of vancomycin or linezolid to critically ill patients with impaired renal function. Eur J Clin Microbiol Infect Dis 2011; 30: 635-643.
21. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ: Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46: 2723-2726.
22. Matsumoto K, Takeda Y, Takeshita A, Fukunaga N, Shigemi A, Yaji K, Shimodozono Y, Yamada K, Ikawa K, Morikawa N: Renal function as a predictor of linezolid-induced thrombocytopenia. Int J Antimicrob Agents 2009; 33: 98-99.
23. Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y, Morikawa N, Takeda Y, Yamada K: Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents 2010; 36: 179-181.
24. Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Kobayashi T, Sadoh S, Morita K, Kamimura H, Karube Y: Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother 2011; 17: 382-387.